Moreover, anti-CXCL16 treatment significantly reduced the percentages of Th17 cells in the BM, spleen, LNs and PB of B-ALL cell-transplanted mice, indicating that anti-CXCL16 treatment impeded the migration of Th17 cells to the leukemia niche in vivo (Fig. 7o). The gene discussed is CXCL16; the disease is leukemia.